Food News and Research

RSS

World Vision receives $19M grant from USAID to help families and communities in Haiti

International relief and development agency World Vision has been awarded a $19 million grant from the U.S. Agency for International Development to help families and communities in Haiti affected by the devastating January 12 earthquake in Port-au-Prince.

24 Feb 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Diagnostic Hybrids, a Quidel Company has received emergency use authorization from the U.S. Food and Drug Administration for its D3® UltraTM 2009 H1N1 Influenza A Virus ID Kit, a monoclonal antibody fluorescent staining kit for the specific identification of 2009 H1N1 influenza A in direct patient specimens or incubated tissue cultures.

23 Feb 2010

Medtronic third-quarter revenues up by 10%

Medtronic, Inc. today reported financial results for the third quarter of fiscal year 2010, which ended January 29, 2010.

23 Feb 2010

Menssana Research develops 85% accurate breath test for pulmonary tuberculosis

A new breath test can detect active pulmonary tuberculosis, according to a report to be published in the journal "Tuberculosis."

23 Feb 2010

Behavioral Neuroscience: Adolescents more susceptible to internal and environmental factors

While the otherworldly behavior of teenagers is well documented, University of Pittsburgh researchers have taken a significant step toward finally unraveling the actual brain activity that can drive adolescents to engage in impulsive, self-indulgent, or self-destructive behavior.

23 Feb 2010

Tel Aviv University unveils new synthetic supplement to stall age-related memory loss

Those who live in industrialized countries have easy access to healthy food and nutritional supplements, but magnesium deficiencies are still common. That's a problem because new research from Tel Aviv University suggests that magnesium, a key nutrient for the functioning of memory, may be even more critical than previously thought for the neurons of children and healthy brain cells in adults.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Humans can harbor bacteria in gallstones, infect others with active typhoid fever

A new study suggests that the bacteria that cause typhoid fever collect in tiny but persistent communities on gallstones, making the infection particularly hard to fight in so-called "carriers" - people who have the disease but show no symptoms.

23 Feb 2010

Also in global health news: Infant, maternal mortality in N. Korea; malaria in Cambodia; Zambia PEPFAR program; Pakistan's anti-polio campaign; U.N. Ambassador responds to Somalia; Myanmar refugees

Higher rates of infant and maternal mortality have lead to a decline of life expectancy in North Korea over the past 15 years, census figures, which were obtained with help form the U.N. Population Fund, said on Monday, Agence France-Presse reports (2/22).

23 Feb 2010

Newborn Possibilities program for babies at-risk for neurological injury

For every 1,000 children born in the U.S. today, two to three are at risk for developing cerebral palsy because of injuries to the brain that may have occurred prior to or during birth. There is currently no cure for cerebral palsy, but Newborn Possibilities is a first-of-its-kind program recently launched in Tucson, which may offer new options for newborns at-risk for neurological injury.

23 Feb 2010

Acute stroke care and clinical outcomes improve substantially with stroke program

Acute stroke care and clinical outcomes have improved significantly at hospitals participating in the American Heart Association/American Stroke Association's Get With The Guidelines-Stroke program, according to a large study in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

23 Feb 2010

Haitian President says up to 300,000 people could have died in quake

The major earthquake in January in Haiti could have killed as many as 300,000 people, an estimate that includes bodies buried in the rubble, Haitian President Rene Preval said on Sunday at a meeting of Latin American and Caribbean leaders in Mexico, Reuters reports.

23 Feb 2010

Star Scientific seeks FDA marketing approval for Ariva-BDL dissolvable tobacco lozenge

Star Scientific, Inc. announced that on Friday, February 19 the company filed an application with the Food & Drug Administration for approval to market Ariva-BDL™ as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009. This submission is the first such application to be filed with the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.

23 Feb 2010

Eon Labs to pay $3.5M for resolving False Claims Act allegations concerning Nitroglycerin SR capsules

Eon Labs Inc. has agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company's drug Nitroglycerin Sustained Release (SR) capsules, the Justice Department announced today. Eon Labs is a subsidiary of Sando Inc., which is in turn a subsidiary of Novartis AG.

23 Feb 2010

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.

23 Feb 2010

FDA grants Fast Track designation for Curemark's CM-AT autism treatment

Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced that its CM-AT autism treatment, now in Phase III clinical trials, has been designated as a Fast Track drug by the U.S. Food and Drug Administration (FDA).

22 Feb 2010

UIC researchers receive federal grant to study effects of TV media on children’s health outcomes

Researchers at the University of Illinois at Chicago Institute for Health Research and Policy have received a $2.2 million federal grant to determine whether or not TV food advertising affects children's diet, physical activity and weight.

22 Feb 2010

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.

22 Feb 2010

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

22 Feb 2010

Food News and Research

World Vision receives $19M grant from USAID to help families and communities in Haiti

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Medtronic third-quarter revenues up by 10%

Menssana Research develops 85% accurate breath test for pulmonary tuberculosis

Behavioral Neuroscience: Adolescents more susceptible to internal and environmental factors

Tel Aviv University unveils new synthetic supplement to stall age-related memory loss

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Humans can harbor bacteria in gallstones, infect others with active typhoid fever

Also in global health news: Infant, maternal mortality in N. Korea; malaria in Cambodia; Zambia PEPFAR program; Pakistan's anti-polio campaign; U.N. Ambassador responds to Somalia; Myanmar refugees

Newborn Possibilities program for babies at-risk for neurological injury

Acute stroke care and clinical outcomes improve substantially with stroke program

Haitian President says up to 300,000 people could have died in quake

Star Scientific seeks FDA marketing approval for Ariva-BDL dissolvable tobacco lozenge

Eon Labs to pay $3.5M for resolving False Claims Act allegations concerning Nitroglycerin SR capsules

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

FDA grants Fast Track designation for Curemark's CM-AT autism treatment

UIC researchers receive federal grant to study effects of TV media on children’s health outcomes

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Understanding cultivated meat and its global potential eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News